Larry A Mole
Overview
Explore the profile of Larry A Mole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belperio P, Shahoumian T, Loomis T, Mole L, Backus L
J Hepatol
. 2018 Sep;
70(1):15-23.
PMID: 30266283
Background & Aim: Understanding the real-world effectiveness of all-oral hepatitis C virus (HCV) regimens informs treatment decisions. We evaluated the effectiveness of daclatasvir + sofosbuvir ± ribavirin (DCV + SOF ...
2.
Backus L, Belperio P, Shahoumian T, Mole L
Hepatology
. 2018 Jan;
68(3):827-838.
PMID: 29377196
Conclusion: Successfully treating hepatitis C virus with DAAs in patients without clinically apparent advanced liver disease translates into a significant mortality benefit. (Hepatology 2018).
3.
Backus L, Belperio P, Shahoumian T, Mole L
Hepatology
. 2017 Jul;
69(2):487-497.
PMID: 28749564
The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral treatment is not well documented. This study evaluated the impact of direct-acting antiviral-induced SVR on all-cause mortality and...
4.
Belperio P, Shahoumian T, Mole L, Backus L
Hepatology
. 2017 Feb;
66(1):27-36.
PMID: 28240789
Conclusion: HBV reactivation of varying severity, even in the setting of isolated hepatitis B core antibody, with or without accompanying hepatitis can occur-though the occurrence of accompanying severe hepatitis was...
5.
Bhattacharya D, Belperio P, Shahoumian T, Loomis T, Goetz M, Mole L, et al.
Clin Infect Dis
. 2017 Feb;
64(12):1711-1720.
PMID: 28199525
Background.: Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF ± RBV)...
6.
Backus L, Belperio P, Shahoumian T, Loomis T, Mole L
Antivir Ther
. 2016 Dec;
22(6):481-493.
PMID: 27934775
Background: Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ±RBV)...
7.
Backus L, Belperio P, Shahoumian T, Loomis T, Mole L
Hepatology
. 2016 Apr;
64(2):405-14.
PMID: 27115523
Unlabelled: Real-world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions. The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been rapid, but variations often...
8.
Backus L, Belperio P, Loomis T, Han S, Mole L
Ann Intern Med
. 2014 Dec;
161(12):926-8.
PMID: 25506867
No abstract available.
9.
Backus L, Belperio P, Loomis T, Mole L
Am J Public Health
. 2014 Aug;
104 Suppl 4:S555-61.
PMID: 25100421
Objectives: We assessed HCV screening and prevalence among veterans and estimated the potential impact of complete birth cohort screening, accounting for the disparate HCV disease burden by race/ethnicity and gender....
10.
Belperio P, Backus L, Ross D, Neuhauser M, Mole L
J Manag Care Spec Pharm
. 2014 May;
20(6):533-40.
PMID: 24856591
Background: The introduction of the first direct-acting antiviral agents (DAAs) for the treatment of hepatitis C virus (HCV), telaprevir and boceprevir, marked a unique event in which 2 disease-changing therapies...